Model-based estimates of risks of disease transmission and economic costs of seven injection devices in sub-Saharan Africa

Bulletin of the World Health Organization

Volumn 80, Issue 11, 2002, Pages 859-870

  Ekwueme, Donatus U ^a,b,c   Weniger, Bruce G ^c   Chen, Robert T ^c  

^a CENTERS FOR DIS CONTR AND PREV   (United States)

^b NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Disease transmission; Hepatitis B transmission; HIV infections transmission; Iatrogenic disease epidemiology; Injections, Jet; Injections instrumentation economics; Needles adverse effects economics; Risk factors; Syringes adverse effects economics

Indexed keywords

DISEASE TRANSMISSION; HEALTH CARE; HEPATITIS; HUMAN IMMUNODEFICIENCY VIRUS;

AFRICA SOUTH OF THE SAHARA; ARTICLE; BLOODBORNE BACTERIUM; COST BENEFIT ANALYSIS; COTE D'IVOIRE; DEVICE; DISEASE TRANSMISSION; DISPOSABLE EQUIPMENT; GHANA; HEALTH CARE COST; HEALTH CARE SYSTEM; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IATROGENIC DISEASE; INJECTION; MODEL; MONTE CARLO METHOD; MULTIVARIATE ANALYSIS; NEEDLE; RISK; SYRINGE; UGANDA;

AFRICA SOUTH OF THE SAHARA; BLOOD-BORNE PATHOGENS; COST OF ILLNESS; COSTS AND COST ANALYSIS; DISEASE TRANSMISSION, HORIZONTAL; DISPOSABLE EQUIPMENT; EQUIPMENT CONTAMINATION; HEALTH CARE COSTS; HEPATITIS B; HIV INFECTIONS; HUMANS; IATROGENIC DISEASE; INJECTIONS; INJECTIONS, JET; MODELS, STATISTICAL; NEEDLES; RISK ASSESSMENT; SYRINGES;

COTE D'IVOIRE; GHANA; UGANDA;

EID: 0036441679     PISSN: 00429686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (92)

1. State of the World's Vaccines and Immunization 1996. Geneva: World Health Organization; 1996. p. 1-161. WHO document WHO/GPV/96.04.
2. Simonsen L, Kane A, Lloyd J, Zaffran M, Kane M. Unsafe injections in the developing world and transmission of bloodborne pathogens: A review. Bulletin of the World Health Organization 1999;77:789-800
3. Dicko M, Oni AQ, Ganivet S, Kone S, Pierre I, Jacquet B. Safety of immunization injections in Africa: Not simply a problem of logistics. Bulletin of the World Health Organization 2000;78:163-9.
4. Aylward B, Kane M, McNair-Scott R, Hu DJ. Model-based estimates of the risk of human immunodeficiency virus and hepatitis B virus transmission through unsafe injections. International Journal of Epidemiology 1995;24:446-52.
5. Aylward B, Lloyd J, Zaffran M, McNair-Scott R, Evans P. Reducing the risk of unsafe injections in immunization programmes: Financial and operational implications of various injection technologies. Bulletin of the World Health Organization 1995;73:531-40.
6. Brito GS, Chen RT, Stefano IC, Campos AM, Oselka G. The risk of transmission of HIV and other blood-born diseases via jet injectors during immunization mass campaigns in Brazil [abstract no. PC-0132]. 10th International Conference on AIDS; 1994 Aug 7-12; Yokohama, Japan. AIDSLINE 10:301. Available from: URL: http://www.aegis.org/pubs/aidsline/1994/dec/ m94c3258.html (accessed on 22 March 2002).
7. Changing needles but not the syringe: An unsafe practice. Weekly Epidemiologial Record 1987;62:345-52.
8. Greaves WL, Hinman AR, Facklam RR, Allman KC, Barrett CL, Stetler HC. Streptococcal abscesses following diphtheria-tetanus toxoid-pertussis vaccination. Pediatric Infectious Diseases 1982;1:388-90.
9. Soeters R, Aus C. Hazards of injectable therapy. Tropical Doctor 1989;19: 124-6.
10. Mann JM, Francis H, Davachi F, Baudoux P, Quinn TC, Nzilambi, et al. Risk factors for human immunodeficiency virus seropositivity among children 1-24 months old in Kinshasa, Zaire. Lancet 1986;2:654-7.
11. Lepage P, Van de Perre P. Nosocomial transmission of HIV in Africa: What tribute is paid to contaminated blood transfusions and medical injections? Infection Control and Hospital Epidemiology 1988;9:200-3.
12. Jagger J, Hunt EH, Brand-Elnaggar J, Pearson RD. Rates of needlestick injury caused by various devices in a university hospital. New England Journal of Medicine 1988;319:284-8.
13. Jagger J, Hunt EH, Pearson RD. Estimated cost of needlestick injuries for six major needled devices. Infection Control and Hospital Epidemiology 1990;11:584-8.
14. Armstrong SE. The cost of needlestick injuries: The impact of safer medical devices. Nursing Economics 1991;9:426-30.
15. Sagoe-Moses C, Pearson RD, Perry J, Jagger J. Risks to health care workers in developing countries. New England Journal of Medicine 2001;345:538-41.
16. Kane M, Clements J, Hu D. Hepatitis B. In: Jamison DT, Mosley HW, Measham AR, Robadilla JL, editors. Disease Control Priorities in Developing Countries. New York: Oxford University Press; 1993. p. 321-30.
17. Report on the Global HIV/AIDS Epidemic. Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS); 2000. pp. 1-137. UNAIDS document UNAIDS/00.13E. Available from: URL: http://www.unaids.org/epidemic_ update/report/Epi_report.pdf (accessed on 23 March 2002).
18. Hu DJ, Kane MA, Heymann DL. Transmission of HIV, hepatitis B virus, and other bloodborne pathogens in health care settings: A review of risk factors and guidelines for prevention. Bulletin of the World Health Organization 1991;69:623-30.
19. Safe Injection - Vital to Health. Geneva: World Health Organization; 1999. Available from: URL: http://www.who.int/vaccines-access/injection_safety/Injections_ Safety/vital_to_Health/(accessed on 23 March 2002).
20. Zaffran M, Lloyd J, Clements J, Stilwell B. A Drive to Safer Injectlons. Geneva: World Health Organization; 1997. WHO document WHO/GPV/SAGE.97/ WP.05.
21. Progress towards global measles control and elimination, 1990-1996. Morbidity and Mortality Weekly Report 1997;46:893-7.
22. World Health Organization, United Nations Children's Fund. WHO-UNICEF Policy Statement for Mass Immunization Campaigns. Geneva: World Health Organization; 1997. p. 1-4. WHO document WHO/EPI/LHIS/97.04 Rev. 1.
23. World Health Organization, United Nations Children's Fund, United Nations Population Fund. Safety of Injections: WHO-UNICEF-UNFPA Joint Statement on the Use of Auto-Disable Syringes in Immunization Services. Geneva: World Health Organization; 1999. p. 1-4. WHO document WHO/V&B/99.25. Available from: URL: http://www.who.int/vaccines-documents/DocsPDF99/www9948.pdf (accessed on 23 March 2002).
24. GPV Declares War on Unsafe Injections. Vaccine and Immunization News 1997;5:1-5. Geneva: World Health Organization. WHO document GPV/VIN/97.03. Available from: URL: http://www.who.int/vaccines-documents/DoxNews/pdf-news/e_vin05.pdf (accessed on 23 March 2002)
25. Lloyd JS, Milstien JB. Auto-disable syringes for immunization: Issues in technology transfer. Bulletin of the World Health Organization 1999;77:1001-7.
26. Kane A, Lloyd J, Zaffran M, Simonsen L, Kane M. Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: Model-based regional estimates. Bulletin of the World Health Organization 1999;77:801-7.
27. Owens DK, Nease RF. Occupational exposure to human immunodeficiency virus and hepatitis B virus: A comparative analysis of risk. American Journal of Medicine 1992;92:503-12.
28. Nelson CM, Sutanto A, Suradana IG. Use of SoloShot autodestruct syringes compared with disposable syringes, in a national immunization campaign in Indonesia. Bulletin of the World Health Organization 1999;77:29-33.
29. Steinglass R, Boyd D, Grabowsky M, Laghari AG, Khan MA, Qavi A, et al. Safety, effectiveness and ease of use of a non-reusable syringe in a developing country immunization programme. Bulletin of the World Health Organization 1995;73:57-63.
30. Device Achieves Breakthrough in Battle Against Spread of AIDS, other Bloodborne Diseases [press release]. Little Elm (TX): Retractable Technologies Inc.; 1997.
31. Younger B, Hunt EH, Robinson C, McLemore C. Impact of a shielded safety syringe on needlestick injuries among health-care workers. Infection Control and Hospital Epidemiology 1992;13:349-53.
32. Coursaget P, Kane MA. Overview of clinical studies in developing countries. In: Ellis RW, editor. Hepatitis B Vaccines in Clinical Practice. New York: Marcel Dekker; 1993. p. 209-28.
33. Ekwueme DU. Comparative Cost Analysis of Injection Delivery Technologies in Sub-Saharan Africa, 28 December 1999 p. 1-128. Consultant's report submitted to the World Health Organization, 1999.
34. Charney W. Retractable safety syringe activation study. Journal of Health Care Safety, Compliance and Infection Control 1998;2:413-5.
35. Canter J, Mackey K, Good LS, Roberto RR, Chin J, Bond WW, et al. An outbreak of hepatitis B associated with jet injections in a weight reduction clinic. Archives of Internal Medicine 1990;150:1923-7.
36. Hoffman PN, Abuknesha RA, Andrews NJ, Samuel D, Lloyd JS. A model to assess the infection potential of jet injectors used in mass immunisation. Vaccine 2001;19:4020-7.
37. Grabowsky M, Hadler SC, Chen RT, Bond WW, De Brito G. Risk of Transmission of Hepatitis B Virus or Human Immunodeficiency Virus from Jet Injectors and from Needles and Syringes. Atlanta (GA): Centers for Disease Control and Prevention, 1994. Unpublished document.
38. Grady GF, Lee VA, Prince AM, Gitnick GL, Fawaz KA, Vyas GN, et al. Hepatitis B immune globulin for accidental exposures among medical personnel: Final report of a multicenter controlled trial. Journal of Infectious Diseases 1978;138:625-38.
39. Seeff LB, Wright EC, Zimmerman HJ. Type B hepatitis after needlestick exposure: Prevention with hepatitis B immune globulin. Annals of internal Medicine 1978;88:285-93.
40. Recommendations for preventing transmission of human immunodeficiency virus and hepatitis B virus to patients during exposure-prone invasive procedures. Morbidity and Mortality Weekly Report Recommendations and Reports 1991;40(RR-8):1-9.
41. Bell DM, Shapiro CN, Culver DH, Martone WJ, Curran JW, Hughes JM. Risk of hepatitis B and human immunodeficiency virus transmission to a patient from an infected surgeon due to percutaneous injury during an invasive procedure: Estimates based on a model. Infectious Agents and Disease 1992;1:263-9.
42. Culver J. Preventing transmission of blood-borne pathogens: A compelling argument for effective device-selection strategies. American Journal of Infection Control 1997;25:430-3.
43. Henderson DK, Fahey BJ, Willy M, Schmitt JM, Carey K, Koziol DE, et al. Risk for occupational transmission of human immunodeficiency virus type 1 (HIV-1) associated with clinical exposures. Annals of internal Medicine 1990;113:740-6.
44. Supply Catalogue. Copenhagen: United Nations Children's Fund; 1997.
45. World Health Organization, United Nations Children's Fund. EPI Product Information Sheets: 1997 Edition. Geneva: World Health Organization. WHO document WHO/EPI/LHIS/97.01.
46. World Health Organization, United Nations Children's Fund. EPI Product Information Sheets: 1998 Supplement. Geneva: World Health Organization. WHO document WHO/EPI/LHIS/98.03.
47. EPI Syringe and Sterilizer Study. Geneva: World Health Organization; 1985. p. 1-28. WHO document EPI/CCIS/85.6.
48. Choice of syringes for the EPI. Weekly Epidemiological Record 1986;61:41-3.
49. Keystone Dental Group. Ped-O-Jet January 1997 Price List. Cherry Hill (NJ): Ped-O-Jet International, Keystone Industries; 1997. p. 1-4.
50. Cost analysis of various vaccine delivery systems. In: Health Tech Product Development Plan - MEDIVAX. Low-Workload Jet Injector. Seattle (WA): Program for Appropriate Technology in Health; 1996. Unpublished document.
51. Department of Vaccines and Biologicals. Assessing the whole cost of injection technologies: Case studies in Africa. In: Technet Consultation, Harare, 6-10 December 1999. Geneva: World Health Organization, 2000. WHO document WHO/ATT/TECHNET.99/Session 3/WP.3. Available from: URL: http://www.who.int/vaccines-documents/DocsPDF00/www536.pdf (accessed on 23 March 2002).
52. Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. 2nd Ed. Oxford: Oxford University Press; 1997.
53. Over M, Bertozzi S, Chin J. Guidelines for rapid estimation of the direct and indirect costs of HIV infection in a developing country. Health Policy 1989;11:169-86.
54. Mansergh G, Haddix AC, Steketee RW, et al. Cost-effectiveness of short-course zidovudine to prevent perinatal HIV type 1 infection in a sub-Saharan African developing country setting. JAMA 1996;276:139-45.
55. The World Factbook 2001. Virginia: McLean (VA): Central Intelligence Agency; 2001. Available from: URL: http://www.cia.gov/cia/publications/factbook/ (accessed on 30 May 2002).
56. Critchfield GC, Willard KE. Probabilistic analysis of decision trees using Monte Carlo simulation. Medical Decision Making 1986;6:85-92.
57. Dobilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo simulation: A practical approach. Medical Decision Making 1985;5:157-77.
58. Dittus RS, Roberts SD, Wilson JR. Quantifying uncertainty in medical decisions. Journal of the American College of Cardiology 1989;14(3 Suppl A):23A-28A.
59. Evans M, Hastings N, Peacock B. Statistical Distributions. 2nd Ed. New York: John Wiley and Sons; 1993.
60. Oakshott L. Business Modeling and Simulation. Washington (DC): Pitman Publishing; 1997.
61. Palisade Corporation. Guide to Using @RISK: Risk Analysis and Simulation Add-in for Microsoft Excel or Lotus 1-2-3, Windows Version. Newfield (NY): Palisade Corporation; 2000.
62. World Bank. Health expenditure, services and use. In: World Development Indicators 2000. Washington (DC): World Bank; 2000. p. 92.
63. Patient exposures to HIV during nuclear medicine procedures. Morbidity and Mortality Weekly Report 1992;41:575-8.
64. Davachi F, Baudoux P, Ndoko K, N'Galy B, Mann J. The economic impact on families of children with AIDS in Kinshasa, Zaire. In: Fleming A, Carballo M, FitzSimons DW, Bailey MR, Mann J, editors. The Global Impact of AIDS. New York: Alan R. Liss; 1988. p. 167-9.
65. Foster S. The Economic Impact of AIDS in Zambia. Washington (DC): World Bank; 1993. Unpublished paper prepared for the Human Resources and Poverty Division.
66. Hersh BS, Popovici F, Apetrei RC, Zolotusca L, Beldescu N, Calomfirescu, A, et al. Acquired immunodeficiency syndrome in Romania. Lancet 1991;338:645-9.
67. Hersh BS, Popovici F, Jezek Z, Satten GA, Apetrei RC, Beldescu N, et al. Risk factors for HIV infection among abandoned Romanian children. AIDS 1993;7:1617-24.
68. Feilden R. Final Report: Choosing a Sustainable Policy for Giving Safe Injections in Romania. New York: United Nations Children's Fund; 1993. Unpublished document.
69. Holding R, Carlsen W. Deadly needles: Fast track to global disaster. San Francisco Chronicle 1998 Oct 27. p. A-1 et seq. Available from: URL: http:// sfgate.com/cgi-bin/article.cgi?file=/chronicle/archive/1998/10/27/ MN52NEE.DTL (accessed on 24 March 2002).
70. Hutin YJF, Harpaz R, Drobeniuc J, Melnic A, Ray C, Favorov M, et al. Injections given in healthcare settings as a major source of acute hepatitis B in Moldova. International Journal of Epidemiology 1999;28:782-6.
71. Spiegel A, Moren A, Varaine F, Baudon D, Rey M. Aspects épidémiologiques et contrôle des épidémies de méningite à méningocoqùe en Afrique [Epidemiologic aspects and control of meningococcal meningitis epidemics in Africa]. Cahiers Santé 1994;4:231-6. In French.
72. Artus JC. Vaccination de masse par le vaccin souche Rockefeller 17D au Sénégal. Utilisation des "Ped-O-Jet" [Mass vaccination with the Rockefeller 17D strain in Senegal. Use of the "Ped-O-Jet"]. Médecine Tropicale 1966;26:527-36. In French.
73. Reis EC, Jacobson RM, Tarbell S, Weniger BG. Taking the sting out of shots: Control of vaccination-associated pain and adverse reactions. Pediatric Annals 1998;27:375-86.
74. Hepatitis B associated with jet gun injection - California. Morbidity and Mortality Weekly Report 1986;35:373-6.
75. Transmission of hepatitis B associated with jet gun injection. Weekly Epidemiological Record 1986;61:309-11.
76. United States Department of Defense. Automatic Jet Hypodermic Injection Units/Withdrawal (DP5C 970147), Fort Detrick (MD): United States Army Medical Material Agency; 1997. Medical material quality control document MMQC-97-1169. Available from: URL: http://review.detrick.army.mil/usamma/mmqc_messages/Q971169.txt (accessed on 27 March 2002).
77. Centers for Disease Control and Prevention (CDC). Needle-Free Injection Technology: Policies (WHO, CDC and DoD). Atlanta (GA): National Immunization Program, CDC. Available from: URL: http://www.cdc.gov/nip/ dev/jetinject.htm#policies (accessed on 4 March 2002).
78. Safety of Injections in Immunization Programmes: WHO Recommended Policy. Geneva: World Health Organization; 1998. p. 1-11. WHO document WHO/ EPI/LHIS/96.05 Rev.1. Available from: URI.: http://www.who.int/gpvdocuments/DocsPDF/www9665.pdf (accessed on 27 March 2002).
79. Centres for Disease Control and Prevention. Jet injectors. In: General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report, Recommendations and Reports 1994;43(RR-1):1-38.
80. Centres for Disease Control and Prevention. Jet injectors. In: General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP). Morbidity and Mortality Weekly Report, Recommendations and Reports 2002;51 (No. RR-2):1-38.
81. Galy M, Genet A, Saliou P. Un progrès dans le domaine de l'injection sans aiguille: Le système Imule® [Progress in the field of needle-free injection: The Imule® system]. ST Pharma Pratiques 1992;4:261-6. In French.
82. Fisch A, Cadilhac P, Vidor E, Prazuck T, Dublanchet A, Lafaix C. Immunogenicity and safety of a new inactivated hepatitis A vaccine: A clinical trial with comparison of administration route. Vaccine 1996;14:1132-6.
83. Parent du Châtelet I, Lang J, Schlumberger M, Vidor E, Soula G, Genet A, et al. Clinical immunogenicity and tolerance studies of liquid vaccines delivered by jet-injector and a new single-use cartridge (Imule®): Comparison with standard syringe injection. Vaccine 1997;15:449-58.
84. Schlumberger M, Parent du Châtelet I, Lafarge H, Genêt A, Gaye AB, Monnereau A, et al, Coût de l'injection d'anatoxine tétanique par injecteur sans aiguille (Imule™) lors d'une vaccination collective au Sénégal: Comparaison avec l'injection par seringues et aiguilles restérilisables [Cost of tetanus toxoid injection by needle-free injector (Imule™) in a mass vaccination in Senegal: Comparison with resterilizable syringes and needles]. Cahiers Santé 1999;9: 319-26. In French.
85. Laufer FN, Chiarello LA. Application of cost-effectiveness methodology to the consideration of needlestick-prevention technology. American Journal of Infection Control 1994;22:75-82.
86. Holding R, Carlsen W. Epidemic ravages caregivers. Thousands die from diseases contracted through needlesticks. San Francisco Chronicle 1998 April 13. p. A-1 et seq. Available from: URL: http://www.sfgate.com/cgi-bin/article.cgi?file=/chronicle/archive/ 1998/04/13/MN64658.DTL (accessed on 24 March 2002).
87. International Health Care Worker Safety Center. State Legislation on Needle Safety, Updated 01/24/02. Charlottesville (VA): University of Virginia Health System; 2002. Available from: URL: http://www.med.virginia.edu/medcntr/centers/epinet/statelist.html (accessed on 24 March 2002).
88. Voelker R. Needlestick bill passes [Quick uptakes]. JAMA 2000;284:2585.
89. Occupational Safety and Health Administration. Occupational Exposure to Bloodborne Pathogens; Needlestick and other Sharps Injuries; Final Rule. Washington (DC): Federal Register; 2001. 29 CFR Part 1910. 66.5318-25. Available from: URL: http:/www.osha-slc.gov/FedReg_osha_pdf/FED20010118A.pdf (accessed on 27 March 2002).
90. Levine MM, Dougan G. Optimism over vaccines administered via mucosal surfaces. Lancet 1998;351:1375-6.
91. Tang D-C, Shi Z, Curiel DT. Vaccination onto bare skin. Nature 1997;388: 729-30.
92. Guerena-Burgueno F, Hall ER, Taylor DN, Cassels FJ, Scott DA, Wolf MK, et al. Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously. Infection and Immunity. 2002; 70:1874-80.